Molecular structure of Pranlukast hemihydrate, CAS Number: 150821-03-7
Pranlukast hemihydrate (CAS 150821-03-7)
Application:
Pranlukast hemihydrate is a subtype specific CysLT1 receptor antagonist
CAS Number:
150821-03-7
Molecular Weight:
490.51
Molecular Formula:
C27H23N5O4•0.5H2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Pranlukast hemihydrate is a leukotriene receptor antagonist that functions by blocking the action of leukotriene D4 at the CysLT1 receptor, thereby inhibiting the physiological effects of leukotrienes. Pranlukast Hemihydrate′s mechanism of action involves binding to the receptor and preventing the activation of downstream signaling pathways, ultimately leading to the reduction of bronchoconstriction, mucus secretion, and inflammation in the airways. By interfering with the leukotriene-mediated inflammatory response, pranlukast hemihydrate plays a role in modulating the immune system′s response to allergens and other triggers. At the molecular level, Pranlukast hemihydrate disrupts the interaction between leukotriene D4 and its receptor, thereby altering the cellular response to inflammatory stimuli.
Pranlukast hemihydrate (CAS 150821-03-7) References
- Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. | Mizoe, T., et al. 2007. J Control Release. 122: 10-5. PMID: 17655963
- Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. | Mizoe, T., et al. 2008. AAPS PharmSciTech. 9: 755-61. PMID: 18563576
- Nanoparticle formulations in pulmonary drug delivery. | Bailey, MM. and Berkland, CJ. 2009. Med Res Rev. 29: 196-212. PMID: 18958847
- One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. | Ohashi, K., et al. 2009. J Control Release. 135: 19-24. PMID: 19121349
- Spray drying technique. I: Hardware and process parameters. | Cal, K. and Sollohub, K. 2010. J Pharm Sci. 99: 575-86. PMID: 19774644
- α-Glucosyl hesperidin induced an improvement in the bioavailability of pranlukast hemihydrate using high-pressure homogenization. | Uchiyama, H., et al. 2011. Int J Pharm. 410: 114-7. PMID: 21419200
- Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: preparation and evaluation. | Baek, MK., et al. 2013. Int J Nanomedicine. 8: 167-76. PMID: 23326192
- Functionally engineered nanosized particles in pharmaceutics: improved oral delivery of poorly water-soluble drugs. | Ozeki, T. and Tagami, T. 2013. Curr Pharm Des. 19: 6259-69. PMID: 23470003
- Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization. | Ha, ES., et al. 2015. Drug Des Devel Ther. 9: 3257-66. PMID: 26150699
- Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations. | Kollipara, S. and Gandhi, RK. 2014. Acta Pharm Sin B. 4: 333-49. PMID: 26579403
- Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein. | Sun, T., et al. 2016. Biotechnol Lett. 38: 1375-80. PMID: 27146207
- Lipid-based dispersions of exemestane for improved dissolution rate and intestinal permeability: in vitro and ex vivo characterization. | Eedara, BB. and Bandari, S. 2017. Artif Cells Nanomed Biotechnol. 45: 917-927. PMID: 27267814
- A simple blending with α-glycosylated naringin produces enhanced solubility and absorption of pranlukast hemihydrate. | Uchiyama, H., et al. 2019. Int J Pharm. 567: 118490. PMID: 31271814
- In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. | Abrahim-Vieira, BA., et al. 2020. An Acad Bras Cienc. 92: e20191445. PMID: 32785428
- Biological Activities and Solubilization Methodologies of Naringin. | Jiang, H., et al. 2023. Foods. 12: PMID: 37372538
Inhibitor of:
CysLT1 Receptor, and LT-β.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pranlukast hemihydrate, 5 mg | sc-215745 | 5 mg | $73.00 |